reports
Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Req...
Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Request and Suspension of Trading of its Securities on the NASDAQ Capital Markets HAYWARD, Calif., June 27, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) (“Anthera” or the “Company”) announced today that it has withdrawn its request for a hearing to appeal the delisting determination of the Staff of the Nasdaq Stock Market (“Nasdaq”) from the Nasdaq Capital Market. The Nasdaq Staff has accepted the Company’s withdrawal and will suspend the trading of the Company’s securities at the open of business o...
DEADLINE ALERT: Brower Piven Reminds Investors Of The Upcoming Deadlin...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) (“Anthera” or the “Company”) common stock during the period between February 10, 2015 and December 27, 2016, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until A...
ANTH INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors...
NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) securities between February 10, 2015 and December 27, 2016. Click here to learn about the case: http://www.wongesq.com/pslra/anthera-pharmaceuticals-inc. There is no cost or obligation to you. According to the complaint, throughout the Class Period Anthera made materially ...
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses I...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) (“Anthera” or the “Company”) common stock during the period between February 10, 2015 and December 27, 2016, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until A...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Co...
NEW YORK--(BUSINESS WIRE)-- Levi & Korsinsky announces it has commenced an investigation of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) (“Anthera Pharmaceuticals”) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors. On November 10, 2016, Anthera announced that “the CHABLIS-SC1 clinical trial with blisibimod for the treatment of systemic lupus erythematosus (SLE) failed to meet its primary endpoint based upon the SLE Responder Index-6 (SRI-6) at 52 weeks.” Then...
QuickView: Upcoming readouts on all programs
Anthera is focused on the rational design of biologic products based on established mechanisms. The most advanced product is Sollpura, a pancreatic enzyme replacement for cystic fibrosis (CF) patients and other chronic pancreatitis, representing a $1bn market. Pivotal results are expected YE16/Q1’17. The company is also developing blisibimod, a novel peptibody BAFF inhibitor in the same class as Benlysta but significantly more potent, for the treatment of severe lupus and IgA nephropathy, with...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.